WALTHAM, Mass.--Genome Therapeutics here has delivered a customized bioinformatics platform to Schering-Plough as part of a research alliance between the two companies aimed at discovering antiinfective agents that are effective against drug-resistant bacteria. The delivery triggered a milestone payment to Genome Therapeutics of an undisclosed sum.
Two years ago, the firms entered into a multiyear alliance worth $43.5 million. The payment for delivering the bioinformatics platform was the drug company's fifth milestone installment. Previous payments, totaling about $11 million, were for such events as delivering a sequence for the Staphylococcus aureus bacteria and providing multiple assays for validated targets. The delivery of PathoGenome, Genome Therapeu tics' microbial and fungal sequence database, to Schering-Plough, is the first bioinformatics transfer between the two firms, a Genome Therapeutics spokesman said.
PathoGenome was released in May and is also used by Bayer AG and Bristol-Myers Squibb. The proprietary bioinformatics platform combines detailed genetic and biological information in a way that lets researchers analyze and compare genomic information to identify potential drug targets.